ClinicalTrials.gg

Program

deudomperidone

Also written as “CIN-102 Dose 1”, “CIN-102 Dose 2” and “CIN-102 Dose 15mg or 10mg”.

Its studies are mostly in Gastroparesis, led by CinDome Pharma.

Furthest: phase 2, since Jul 17, 20194 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
CinDome Pharma40 open or runningphase 2since Jul 17, 2019Jul 17, 2019none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 17, 2019First study: phase 2 study in GastroparesisFirst studyNCT04026997 · 72 enrolled · United States
  2. Dec 12, 2019Phase 2 study in Diabetic GastroparesisNCT04208698 · 2 enrolled · United States
  3. Mar 16, 2023Phase 2 study in GastroparesisNCT05832151 · 382 enrolled · United States
  4. Feb 14, 2025Phase 2 study in GastroparesisNCT06899217 · 416 enrolled · United States

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06899217Gastroparesis · United States2CompletedMay 7, 2026416
NCT05832151Gastroparesis · United States2CompletedNov 14, 2025382
NCT04208698Diabetic Gastroparesis · United States2TerminatedMar 31, 20202
NCT04026997Gastroparesis · United States2TerminatedDec 17, 202072

How it is read

Names in the registry

  • “CIN-102 Dose 1”, 2 entries
  • “CIN-102 Dose 2”, 2 entries
  • “CIN-102 Dose 15mg or 10mg”, 1 entry
  • “CIN-102 Dose 15mg”, 1 entry
  • “CIN-102 Dose 10mg”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.
deudomperidone (CinDome Pharma): development program | ClinicalTrials.gg